Item 8.01 Other Events.

On September 13, 2021, Adaptimmune Therapeutics plc ("Adaptimmune") issued a press release announcing updated data from its Phase 1 SURPASS trial in multiple solid tumors to be presented in a digital poster at the European Society for Medical Oncology (ESMO) annual meeting. The poster will be displayed on the ESMO congress website on September 16, 2021. The Company has also released a video of Adrian Rawcliffe, Adaptimmune's Chief Executive Officer, and Elliot Norry, Adaptimmune's Chief Medical Officer, describing these data in greater detail. The press release is furnished as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.



(d)  Exhibits.

Exhibit No.                           Description of Exhibit

   99.1          Press release dated September 13, 2021

    104        Cover Page Interactive Date File (embedded within the Inline XBRL
               document)

© Edgar Online, source Glimpses